tbuckley/cabot-search huggingface dataset:
Role of GADD45α as a potential therapeutic target for prostate cancer
Authors: R. Singal, K. Ramachandran, G. Gopisetty, L. Navarro, E. Gordian, M. Manoharan
Journal: Journal of Clinical Oncology (2007)

10566 Background: Defects in the apoptotic pathway contribute to uncontrolled cell proliferation of cancer cells and confer resistance to chemotherapeutic drugs. Understanding the mechanisms of deregulation of apoptosis related genes would enable targeted treatment methods to improve the efficacy of chemotherapy. Growth Arrest and DNA Damage inducible, alpha (GADD45a) mediates cytotoxicity of docetaxel chemotherapy. We examined the mechanism of regulation of GADD45a in prostate cancer cells and the effect of its upregulation on sensitivity to docetaxel chemotherapy. Methods: Levels of GADD45a in Du145, LNCaP and PC3 were analyzed by real time reverse transcriptase PCR and western blotting. DNA methylation was studied by bisulfite sequencing. Chromatin immunoprecipitation was used to study interaction of methyl binding proteins to GADD45 5’ sequence. Cytotoxicity after drug treatment was measured by MTT cell proliferation assay. Apoptosis assays were done by Annexin V/propidium iodide staining followed by flow cytometry. Results: Levels of expression of GADD45a in Du145 and LNCaP cells were lower than that in PC3. A 4 CpG region upstream of the proximal promoter region was methylated in Du145 and LNCaP cells. Methylation was reversed by treatment of Du145 and LNCaP cells with DNA methyl transferase (DNMT) inhibitors such as 5- Azacytidine or 5- Aza deoxycytidine leading to reactivation of GADD45a expression in these cells. This region was also frequently methylated in prostate cancer tissues. Methyl binding protein, MeCP2 was associated with the methylated 4 CpGs in Du145 and knock down of MeCP2 by transfection of MeCP2 siRNA vector in Du145 cells (Du145-MeCP2-ve) led to increased expression of GADD45a, without affecting the methylation status of the gene. Enhanced sensitivity to docetaxel was observed by upregulation of GADD45a in Du145 cells by (a) recombinant expression of GADD45a (b) downregulation of MeCP2 and (c) pretreatment with 5-Azacytidine. Conclusions: GADD45a is frequently deregulated in prostate cancer by methylation of 5’ 4 CpG region and is a potential therapeutic target for treatment of prostate cancer. [Table: see text]
Population-Based Quality Indicators for End-of-Life Cancer Care
Authors: Lesley Anne Henson, Polly Edmonds, Anna Johnston, Halle Elizabeth Johnson, Clarissa Ng Yin Ling, Alexandros Sklavounos, Clare Ellis-Smith, Wei Gao
Journal: JAMA Oncology (2019)

<h3>Importance</h3> Improving the quality of cancer care is an international priority. Population-based quality indicators (QIs) are key to this process yet remain almost exclusively used for evaluating care during the early, often curative, stages of disease. <h3>Objectives</h3> To identify all existing QIs for the care of patients with cancer who have advanced disease and/or are at the end of life and to evaluate each indicator's measurement properties and appropriateness for use. <h3>Evidence Review</h3> For this systematic review, 5 electronic databases (MEDLINE, Embase, CINAHL, PsycINFO, and the Cochrane Library) were searched from inception through February 4, 2019, for studies describing the development, review, and/or testing of QIs for the care of patients with cancer who have advanced disease and/or are at the end of life. For each QI identified, descriptive information was extracted and 6 measurement properties (acceptability, evidence base, definition, feasibility, reliability, and validity) were assessed using previously established criteria, with 4 possible ratings: positive, intermediate, negative, and unknown. Ratings were collated and each QI classified as appropriate for use, inappropriate for use, or of limited testing. Among the QIs determined as appropriate for use, a recommended shortlist was generated by excluding those that were specific to patient subgroups and/or care settings; related QIs were identified, and the indicator with the highest rating was retained. <h3>Findings</h3> The search yielded 7231 references, 35 of which (from 28 individual studies) met the eligibility criteria. Of 288 QIs extracted (260 unique), 103 (35.8%) evaluated physical aspects of care and 109 (37.8%) evaluated processes of care. Quality indicators relevant to psychosocial (18 [6.3%]) or spiritual and cultural (3 [1.0%]) care domains were limited. Eighty QIs (27.8%) were determined to be appropriate for use, 116 (40.3%) inappropriate for use, and 92 (31.9%) of limited testing. The measurement properties with the fewest positive assessments were acceptability (38 [13.2%]) and validity (63 [21.9%]). Benchmarking data were reported for only 16 QIs (5.6%). The final 15 recommended QIs came from 6 studies. <h3>Conclusions and Relevance</h3> The findings suggest that only a small proportion of QIs developed for the care of patients with cancer who have advanced disease and/or are at the end of life have received adequate testing and/or are appropriate for use. Further testing may be needed, as is research to establish benchmarking data and to expand QIs relevant to psychosocial, cultural, and spiritual care domains.
Home Gun Safety Queries in Well-Child Visits
Authors: Carole H. Stipelman, Greg Stoddard, Kyle Bata, Bhanu Muniyappa, Elly Trepman, Elizabeth Smith
Journal: JAMA Pediatrics (2019)

without ASD.This disparity was more pronounced among children with ASD who had developmental comorbidities.These findings may be due to several factors, including underlying sensory sensitivities, comorbidity of conditions associated with pain (eg, cerebral palsy, genetic syndromes impacting gastrointestinal and other systems), and, by extension, a higher frequency of medical procedures that can lead to short-term or long-term pain.Study findings suggest the need for improved awareness and modalities for pain assessment as well as incorporating pain management as part of regular therapy for children with ASD.Future studies are needed to determine pain characteristics (eg, location) and if pain is implicated in short-term (eg, activity interference) or long-term (eg, noncommunicable diseases) adverse health outcomes for this population.
EP1.14-03 Driver Genes as Predictive Indicators of Brain Metastasis in Patients with Advanced NSCLC: EGFR and ALK as Well as RET Gene Mutations
Authors: H. Wang, Z. Wang, J. Ma, G. Zhang, M. Zhang, X. Zhang, H. Li, X. Zheng, Z. Ma
Journal: Journal of Thoracic Oncology (2019)
Methylated miR-124, -137, and -34b/c as predictive biomarkers for ulcerative colitis-associated colorectal neoplasia.
Authors: Yuji Toiyama, Keun Hur, Koji Tanaka, Yasuhiro Inoue, Tsutomu Tabata, Masato Kusunoki, C. Richard Boland, Ajay Goel
Journal: Journal of Clinical Oncology (2013)

e14631 Background: Accumulating evidence suggests that microRNAs (miRNAs) can be targets of methylation-induced silencing in colorectal cancer, which can occur in an age-dependent manner, and constitutes an epigenetic “field defect”. We hypothesized whether methylation of miR-124, -137 and -34b/c can predict colorectal neoplasia in patients with ulcerative colitis (UC). Methods: We examined 185 samples from 70 UC patients (45 patients without neoplasia, 12 with dysplasia and 13 with cancers) for the methylation status of miR-124, -137 and -34b/c by quantitative bisulfite pyrosequencing analysis. In addition, expression levels of these 3 miRNAs in dysplastic (n=12), cancerous (n=13) and non-neoplastic UC mucosa (n=20) were quantified by TaqMan qRT-PCR. Results: MiR-124 and -137 methylation levels were significantly higher in rectal tissues than in proximal mucosa from non-neoplastic UC tissues, and were significantly associated with age and disease duration in rectal tissues. Methylation levels of all 3 miRNAs were significantly higher in dysplasia and cancer compared to mucosa without neoplasia, and showed a “field defect” in the non-neoplastic rectal tissues from patients with cancer . Receiver operating characteristic (ROC) analysis revealed that methylation levels of all 3 miRNAs in non-neoplastic rectal tissues could discriminate patients with cancer from those without (miR-124 AUC value = 0.74; miR-137 AUC = 0.79; miR-34b/c AUC=0.72). Furthermore, methylated miR-137 in non-neoplastic rectal tissues allowed discrimination of UC patients with neoplasia from those without (AUC = 0.76), and independently predicted neoplasia (OR= 5.55; 95% CI: 1.40–22.05; P = 0.0148). Expression levels of all 3 miRNAs were significantly downregulated in dysplasia or cancer compared to non-neoplastic UC mucosa, and the expression and methylation were negatively correlated. Conclusions: Methylation of miR-124, -137 and -34b/c in rectal biopsies, particularly miR-137, may serve as novel predictive biomarkers for neoplasia in UC patients. Restoration of expression by reversing their methylation status could be an attractive strategy to slow or reverse age-related UC-associated neoplasia.
P2.15-11 Favorable Long Term Survival After Initially Palliative Resection for a Giant Primary Rib Osteosarcoma with Severe Mediastinal Shifting
Authors: K. Sinn, E. Gschwandtner, R. Hritcu, J.M. Matilla, K. Hötzenecker, G. Lang, S. Taghavi, W. Klepetko, M.A. Hoda, T. Klikovits
Journal: Journal of Thoracic Oncology (2019)
Identification of Cardiac Magnetic Resonance Imaging Thresholds for Risk Stratification in Pulmonary Arterial Hypertension
Authors: Robert A. Lewis, Christopher S. Johns, Marcella Cogliano, David Capener, Euan Tubman, Charlie A. Elliot, Athanasios Charalampopoulos, Ian Sabroe, A. A. Roger Thompson, Catherine G. Billings, Neil Hamilton, Kathleen Baster, Peter J. Laud, Peter M. Hickey, Jennifer Middleton, Iain J. Armstrong, Judith A. Hurdman, Allan Lawrie, Alexander M. K. Rothman, Jim M. Wild, Robin Condliffe, Andrew J. Swift, David G. Kiely
Journal: American Journal of Respiratory and Critical Care Medicine (2019)

Rationale: Pulmonary arterial hypertension (PAH) is a life-shortening condition. The European Society of Cardiology and European Respiratory Society and the REVEAL (North American Registry to Evaluate Early and Long-Term PAH Disease Management) risk score calculator (REVEAL 2.0) identify thresholds to predict 1-year mortality.Objectives: This study evaluates whether cardiac magnetic resonance imaging (MRI) thresholds can be identified and used to aid risk stratification and facilitate decision-making.Methods: Consecutive patients with PAH (n = 438) undergoing cardiac MRI were identified from the ASPIRE (Assessing the Spectrum of Pulmonary Hypertension Identified at a Referral Center) MRI database. Thresholds were identified from a discovery cohort and evaluated in a test cohort.Measurements and Main Results: A percentage-predicted right ventricular end-systolic volume index threshold of 227% or a left ventricular end-diastolic volume index of 58 ml/m2 identified patients at low (<5%) and high (>10%) risk of 1-year mortality. These metrics respectively identified 63% and 34% of patients as low risk. Right ventricular ejection fraction >54%, 37-54%, and <37% identified 21%, 43%, and 36% of patients at low, intermediate, and high risk, respectively, of 1-year mortality. At follow-up cardiac MRI, patients who improved to or were maintained in a low-risk group had a 1-year mortality <5%. Percentage-predicted right ventricular end-systolic volume index independently predicted outcome and, when used in conjunction with the REVEAL 2.0 risk score calculator or a modified French Pulmonary Hypertension Registry approach, improved risk stratification for 1-year mortality.Conclusions: Cardiac MRI can be used to risk stratify patients with PAH using a threshold approach. Percentage-predicted right ventricular end-systolic volume index can identify a high percentage of patients at low-risk of 1-year mortality and, when used in conjunction with current risk stratification approaches, can improve risk stratification. This study supports further evaluation of cardiac MRI in risk stratification in PAH.
EP1.15-05 Surgical Outcomes of Pulmonary Metastasectomy for Head and Neck Cancer: A Single Institutional Retrospective Study
Authors: T. Ochi, H. Wada, T. Yamamoto, J. Morimoto, Y. Sakairi, H. Suzuki, T. Nakajima, I. Yoshino
Journal: Journal of Thoracic Oncology (2019)
P1.01-28 Mutational Heterogeneity Between Primary Pulmonary Cancer Lesions and Matched Brain Metastases
Authors: L. Li, Y. Chen, H. Tian, D. Zhou, D. Zhou, X. Lin, K. Yin, H. Feng, W. Guo, Z. Xie, W. Yan, Z. Lv, D. Lu, X. Yang, Y. Wu, X. Zhang
Journal: Journal of Thoracic Oncology (2019)
P1.14-10 The Landscape of RET Genomic Alterations in Chinese Non-Small Cell Lung Cancer Patients
Authors: X. Liu, Y. Wei, X. Fan, M. Ma, J. Liu, S. Wen, M. Li, D. Jiang, Y. Yu, L. Song, Q. Cui, H. Chen, A. Liu, K. Wang, Y. Qu
Journal: Journal of Thoracic Oncology (2019)
Cryoballoon or Radiofrequency Ablation for Atrial Fibrillation Assessed by Continuous Monitoring
Authors: Jason G. Andrade, Jean Champagne, Marc Dubuc, Marc W. Deyell, Atul Verma, Laurent Macle, Peter Leong-Sit, Paul Novak, Mariano Badra-Verdu, John Sapp, Iqwal Mangat, Clarence Khoo, Christian Steinberg, Matthew T. Bennett, Anthony S.L. Tang, Paul Khairy, Ratika Parkash, Peter Guerra, Katia Dyrda, Lena Rivard, Normand Racine, Lawrence Sterns, Rick Leather, Colette Seifer, Umjeet Jolly, Jean-Marc Raymond, Jean-Francois Roux, Isabelle Nault, Jean-Francois Sarrazin, Krishnan Ramanathan, Christopher Cheung, Christopher Fordyce, Jimmy McKinney, Christina Luong, Jacques Rizkallah, Paul Angaran, Andrew Ha, Benedict Glover, Allan Skanes, Lorne Gula
Journal: Circulation (2019)

Advanced generation ablation technologies have been developed to achieve more effective pulmonary vein isolation (PVI) and minimize arrhythmia recurrence after atrial fibrillation (AF) ablation.We randomly assigned 346 patients with drug-refractory paroxysmal AF to contact force-guided radiofrequency ablation (CF-RF; n=115), 4-minute cryoballoon ablation (Cryo-4; n=115), or 2-minute cryoballoon ablation (Cryo-2; n=116). Follow-up was 12 months. The primary outcome was time to first documented recurrence of symptomatic or asymptomatic atrial tachyarrhythmia (AF, atrial flutter, or atrial tachycardia) between days 91 and 365 after ablation or a repeat ablation procedure at any time. Secondary end points included freedom from symptomatic arrhythmia and AF burden. All patients received an implantable loop recorder.One-year freedom from atrial tachyarrhythmia defined by continuous rhythm monitoring was 53.9%, 52.2%, and 51.7% with CF-RF, Cryo-4, and Cryo-2, respectively (P=0.87). One-year freedom from symptomatic atrial tachyarrhythmia defined by continuous rhythm monitoring was 79.1%, 78.2%, and 73.3% with CF-RF, Cryo-4, and Cryo-2, respectively (P=0.26). Compared with the monitoring period before ablation, AF burden was reduced by a median of 99.3% (interquartile range, 67.8%-100.0%) with CF-RF, 99.9% (interquartile range, 65.3%-100.0%) with Cryo-4, and 98.4% (interquartile range, 56.2%-100.0%) with Cryo-2 (P=0.36). Serious adverse events occurred in 3 patients (2.6%) in the CF-RF group, 6 patients (5.3%) in the Cryo-4 group, and 7 patients (6.0%) in the Cryo-2 group, with no significant difference between groups (P=0.24). The CF-RF group had a significantly longer procedure duration but significantly shorter fluoroscopy exposure (P<0.001 vs cryoballoon groups).In this multicenter, randomized, single-blinded trial, CF-RF and 2 different regimens of cryoballoon ablation resulted in no difference in 1-year efficacy, which was 53% by time to first recurrence but >98% burden reduction as assessed by continuous cardiac rhythm monitoring.URL: https://www.clinicaltrials.gov. Unique identifier: NCT01913522.
P2.05-12 Analysis of Biomarkers in Lung Cancer in Spain
Authors: D. Rodriguez-Abreu, T. Moran, R. Lopez Castro, M. Guirado, C. Camps, B. Nunez, J. Bosch-Barrera, R. Bernabe, M. Lazaro, R. Garcia Campelo, J.L. Gonzalez Larriba, B. Massuti, A.L. Ortega, M. Domine, M.a. Sala, A. Padilla, E. Del Barco, J. Oramas, R. Blanco, A. Estival, G. Benitez, M. Provencio
Journal: Journal of Thoracic Oncology (2019)
EP1.04-38 A Case of Lichenoid Reaction as Late and Uncommon Immune-Related Skin Toxicity During Nivolumab Treatment
Authors: A. Catino, R. Filannino, L. Fucci, D. Galetta, M. Guida, G. Del Bene, V. Longo, M. Montrone, F. Pesola, P. Pizzutilo, S. Strippoli
Journal: Journal of Thoracic Oncology (2019)
P2.03-43 WTAP Activates Oncogenes and Accelerates Tumor Aggressiveness Through Adding m6A RNA Modification in Non-Small-Cell Lung Cancer
Authors: K. Yoshimura, Y. Inoue, K. Tsuchiya, Y. Iwashita, T. Kahyo, A. Kawase, M. Tanahashi, Y. Suzuki, M. Karayama, H. Ogawa, N. Inui, K. Funai, K. Shinmura, H. Niwa, T. Suda, H. Sugimura
Journal: Journal of Thoracic Oncology (2019)
MA05.01 Second or Third Line Anti-PD-1 Therapy After Multimodality Therapy Including Total Pleurectomy in Malignant Pleural Mesothelioma
Authors: L. Lang-Lazdunski, Y.Z. Zhang, S. Popat, M. O'Brien, J. Steele, T. Newsom-Davis, A. Scherpereel, H. Bouchaab, A. Rice, A. Nicholson
Journal: Journal of Thoracic Oncology (2019)
Differential 18F-FDG and 18F-Fluciclovine Uptake Pattern in a Patient With Poorly Differentiated Adenocarcinoma of the Lung and Prostate Cancer Biochemical Recurrence
Authors: Nghi C. Nguyen, Ashok Muthukrishnan, James M. Mountz
Journal: Clinical Nuclear Medicine (2019)

Abstract A 72-year-old man with a history of T1cN0M0 prostate adenocarcinoma and rising prostate-specific antigen underwent a fluciclovine PET/CT scan that showed high uptake in several para-aortic nodes, suspicious for prostate cancer. A right upper lobe single pulmonary nodule (SPN), demonstrated only mild uptake, which raised the suspicion for a lung primary. Subsequent FDG PET/CT showed high uptake in the SPN, revealing poorly differentiated adenocarcinoma at biopsy, but with no abnormal uptake in the para-aortic nodes. This case highlights the complementary potential of fluciclovine and FDG PET in patients with a history of prostate cancer biochemical recurrence and SPN.
Placebo Effects of Nurses’ Communication alongside Standard Medical Care on Pain and Other Outcomes: A Randomized Controlled Trial in Clinical Tonsillectomy Care
Authors: Liesbeth M. van Vliet, Marc B. Godfried, Gerard W. van Deelen, Menno Kaunang, Ted J. Kaptchuk, Sandra van Dulmen, Bram Thiel, Jozien M. Bensing
Journal: Psychotherapy and Psychosomatics (2019)
Shared genetic and experimental links between obesity-related traits and asthma subtypes in UK Biobank
Authors: Zhaozhong Zhu, Yanjun Guo, Huwenbo Shi, Cong-Lin Liu, Ronald Allan Panganiban, Wonil Chung, Luke J. O'Connor, Blanca E. Himes, Steven Gazal, Kohei Hasegawa, Carlos A. Camargo, Lu Qi, Miriam F. Moffatt, Frank B. Hu, Quan Lu, William O.C. Cookson, Liming Liang
Journal: Journal of Allergy and Clinical Immunology (2019)
Suppression of LIM Kinase 1 and LIM Kinase 2 Limits Glioblastoma Invasion
Authors: Joseph Chen, Badriprasad Ananthanarayanan, Kelsey S. Springer, Kayla J. Wolf, Sharon M. Sheyman, Vivien D. Tran, Sanjay Kumar
Journal: Cancer Research (2019)

Abstract The aggressive brain tumor glioblastoma (GBM) is characterized by rapid cellular infiltration of brain tissue, raising the possibility that disease progression could potentially be slowed by disrupting the machinery of cell migration. The LIM kinase isoforms LIMK1 and LIMK2 (LIMK1/2) play important roles in cell polarization, migration, and invasion and are markedly upregulated in GBM and many other infiltrative cancers. Yet, it remains unclear whether LIMK suppression could serve as a viable basis for combating GBM infiltration. In this study, we investigated effects of LIMK1/2 suppression on GBM invasion by combining GBM culture models, engineered invasion paradigms, and mouse xenograft models. While knockdown of either LIMK1 or LIMK2 only minimally influenced invasion in culture, simultaneous knockdown of both isoforms strongly reduced the invasive motility of continuous culture models and human GBM tumor-initiating cells (TIC) in both Boyden chamber and 3D hyaluronic acid spheroid invasion assays. Furthermore, LIMK1/2 functionally regulated cell invasiveness, in part, by disrupting polarized cell motility under confinement and cell chemotaxis. In an orthotopic xenograft model, TICs stably transduced with LIMK1/2 shRNA were implanted intracranially in immunocompromised mice. Tumors derived from LIMK1/2 knockdown TICs were substantially smaller and showed delayed growth kinetics and more distinct margins than tumors derived from control TICs. Overall, LIMK1/2 suppression increased mean survival time by 30%. These findings indicate that LIMK1/2 strongly regulate GBM invasive motility and tumor progression and support further exploration of LIMK1/2 as druggable targets. Significance: Targeting the actin-binding proteins LIMK1 and LIMK2 significantly diminishes glioblastoma invasion and spread, suggesting the potential value of these proteins as therapeutic targets.
P2.14-61 Acquired Resistance to Entrectinib Associated with Activation of RAS Signaling Pathway in ROS1-Rearranged Non-Small Cell Lung Cancer
Authors: B.M. Ku, H.A. Jung, J. Sun, S. Lee, J.S. Ahn, K. Park, M. Ahn
Journal: Journal of Thoracic Oncology (2019)
P1.04-47 Tumor Mutation Burden Through Hybrid Capture – Circulating Tumor DNA May Predict Response to Immunotherapy in NSCLC
Authors: R. Grinberg, L. Roisman, S. Geva, M. Lefterova, K. Quinn, L. Soussan Gutman, A. Dvir, R. Yair, R. Lanman, D. Mehta, L. Kiedrowski, L. Raez, N. Peled
Journal: Journal of Thoracic Oncology (2019)
OA11.05 Optimizing Resources with Immunotherapy in Developing Countries: Experience in a Reference Center in Mexico
Authors: O. Macedo-Perez, I. Lyra Gonzalez, L. Bornstein, K. Campos-Peralta, J. Aguilar-Ponce, A. Gomez-Ponce, A. Herrera-Gomez, E. Jimenez-Fuentes
Journal: Journal of Thoracic Oncology (2019)
MA09.11 Mechanisms of Resistance to MET Tyrosine Kinase Inhibitors in Patients with MET Exon 14 Mutant Non-Small Cell Lung Cancer
Authors: G. Recondo, M. Bahcall, L. Sholl, G. Leonardi, B. Ricciuti, T. Nguyen, D. Venkatraman, G. Lamberti, R. Umeton, P. Jänne, M. Awad
Journal: Journal of Thoracic Oncology (2019)
P1.11-11 Initial Discovery of Exhaled Small Polar Energetics-Related Metabolites by GC-MS for Lung Cancer Risk Assessment
Authors: S. Spivack, M.K. Shi, D. Patel, A. Desai, J. Dobkin, C. Shah, D. Hosgood, K. Ye, Y. Qiu, I. Kurland
Journal: Journal of Thoracic Oncology (2019)
EP1.04-47 Chronic and Severe Non-Lichenoid Oral Ulcers Induced by Nivolumab: Diagnostic and Therapeutic Challenge
Authors: A.F. Cardona, A. Ruiz-Patiño, L. Ricaurte, L.L. Rojas, Z.L. Zatarain Barrón, F. Barrón, O.G. Arrieta
Journal: Journal of Thoracic Oncology (2019)
Reply to Lipworth <i>et al.</i>: Sex Hormones and Asthma: Don’t Forget Progesterone
Authors: Yueh-Ying Han, Erick Forno, Juan C. Celedón
Journal: American Journal of Respiratory and Critical Care Medicine (2019)

burden: lung volume reduction surgery and lung transplantation (2).Although both these therapies can have significant benefits to patients, they also have significant complications and costs associated with them that far exceed those that have been reported in patients undergoing endobronchial lung volume reduction therapy (2, 3).We also wholeheartedly agree with Dr. Jain that future research should focus on better predictors of patient outcomes, the minimization of risk, and providing improved outcomes in the most cost-effective fashion.
MA06.06 A Phase III Study of Adjuvant Chemotherapy in Patients with Completely Resected, Node-Negative Non-Small Cell Lung Cancer
Authors: H. Kunitoh, H. Sakurai, M. Tsuboi, M. Wakabayashi, M. Okada, K. Suzuki, N. Ikeda, M. Takahama, M. Takenoyama, Y. Ohde, K. Yoshiya, I. Matsumoto, M. Yamashita, T. Marutsuka, H. Date, T. Hasumi, Y. Yamashita, N. Okumura, S. Watanabe, H. Asamura
Journal: Journal of Thoracic Oncology (2019)